Aytu BioPharma Statistics

Total Valuation

Aytu BioPharma has a market cap or net worth of $22.62 million. The enterprise value is $18.39 million.

Market Cap	22.62M
Enterprise Value	18.39M

Important Dates

The last earnings date was Thursday, November 13, 2025, after market close.

Earnings Date	Nov 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Aytu BioPharma has 10.19 million shares outstanding. The number of shares has increased by 25.31% in one year.

Current Share Class	10.19M
Shares Outstanding	10.19M
Shares Change (YoY)	+25.31%
Shares Change (QoQ)	+186.78%
Owned by Insiders (%)	5.41%
Owned by Institutions (%)	9.99%
Float	7.04M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.25
Forward PS	0.57
PB Ratio	0.95
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.29
EV / EBITDA	3.05
EV / EBIT	15.60
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.23, with a Debt / Equity ratio of 1.23.

Current Ratio	1.23
Quick Ratio	1.00
Debt / Equity	1.23
Debt / EBITDA	4.34
Debt / FCF	n/a
Interest Coverage	0.37

Financial Efficiency

Return on equity (ROE) is -50.23% and return on invested capital (ROIC) is 1.48%.

Return on Equity (ROE)	-50.23%
Return on Assets (ROA)	0.61%
Return on Invested Capital (ROIC)	1.48%
Return on Capital Employed (ROCE)	2.00%
Revenue Per Employee	$767,422
Profits Per Employee	-$157,482
Employee Count	83
Asset Turnover	0.53
Inventory Turnover	1.89

Taxes

In the past 12 months, Aytu BioPharma has paid $32,000 in taxes.

Income Tax	32,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +41.40% in the last 52 weeks. The beta is 0.29, so Aytu BioPharma's price volatility has been lower than the market average.

Beta (5Y)	0.29
52-Week Price Change	+41.40%
50-Day Moving Average	2.15
200-Day Moving Average	1.90
Relative Strength Index (RSI)	56.25
Average Volume (20 Days)	47,622

Short Selling Information

The latest short interest is 487,373, so 4.78% of the outstanding shares have been sold short.

Short Interest	487,373
Short Previous Month	499,690
Short % of Shares Out	4.78%
Short % of Float	6.92%
Short Ratio (days to cover)	6.35

Income Statement

In the last 12 months, Aytu BioPharma had revenue of $63.70 million and -$13.07 million in losses. Loss per share was -$1.92.

Revenue	63.70M
Gross Profit	43.03M
Operating Income	1.18M
Pretax Income	-13.28M
Net Income	-13.07M
EBITDA	6.03M
EBIT	1.18M
Loss Per Share	-$1.92

Full Income Statement

Balance Sheet

The company has $32.63 million in cash and $28.40 million in debt, giving a net cash position of $4.23 million or $0.41 per share.

Cash & Cash Equivalents	32.63M
Total Debt	28.40M
Net Cash	4.23M
Net Cash Per Share	$0.41
Equity (Book Value)	23.17M
Book Value Per Share	2.34
Working Capital	15.12M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$1.37 million and capital expenditures -$92,000, giving a free cash flow of -$1.46 million.

Operating Cash Flow	-1.37M
Capital Expenditures	-92,000
Free Cash Flow	-1.46M
FCF Per Share	-$0.14

Full Cash Flow Statement

Margins

Gross margin is 67.56%, with operating and profit margins of 1.85% and -20.52%.

Gross Margin	67.56%
Operating Margin	1.85%
Pretax Margin	-20.85%
Profit Margin	-20.52%
EBITDA Margin	9.46%
EBIT Margin	1.85%
FCF Margin	n/a

Dividends & Yields

Aytu BioPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-25.31%
Shareholder Yield	-25.31%
Earnings Yield	-57.79%
FCF Yield	-6.44%

Analyst Forecast

The average price target for Aytu BioPharma is $9.17, which is 313.06% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$9.17
Price Target Difference	313.06%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on January 6, 2023. It was a reverse split with a ratio of 1:20.

Last Split Date	Jan 6, 2023
Split Type	Reverse
Split Ratio	1:20

Scores

Aytu BioPharma has an Altman Z-Score of -2.95 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.95
Piotroski F-Score	4